NEW YORK--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Company has appointed three leading, internationally recognized physicians to its newly formed Scientific Advisory Board (“SAB”). The newly appointed members bring expertise in regional cancer therapies, melanoma, neuroendocrine tumors, colorectal cancer and cancers of the limbs. These experts will contribute to the continued development of Delcath Systems’ percutaneous hepatic perfusion (“PHP”) system, a technology designed to isolate and deliver high doses of anti-cancer agents to specific organs or regions of the body, while minimizing the exposure of the drugs to the rest of the body. The System is currently being tested for hepatocellular carcinoma and metastatic liver cancers in Phase II and III clinical trials. The new members include Alexander M.M. Eggermont, MD, PhD, of the Erasmus University Medical Center – Daniel den Hoed Cancer Center in Rotterdam; Douglas L. Fraker, MD, of the University of Pennsylvania Health System; and Larry K. Kvols, MD, of the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida.
